Effect of DNA Polymerases and High Mobility Group Protein 1 on the Carrier Ligand Specificity for Translesion Synthesis past Platinum−DNA Adducts
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Translesion synthesis past Pt-DNA adducts can affect both the cytotoxicity and mutagenicity of the platinum adducts. We have shown previously that the extent of replicative bypass in vivo is influenced by the carrier ligand of platinum adducts. The specificity of replicative bypass may be determined by the DNA polymerase complexes that catalyze translesion synthesis past Pt-DNA adducts and/or by DNA damage-recognition proteins that bind to the Pt-DNA adducts and block translesion replication. In the present study, primer extension on DNA templates containing site-specifically placed cisplatin, oxaliplatin, JM216, or chlorodiethylenetriamine-Pt adducts revealed that the eukaryotic DNA polymerases beta, zeta, gamma, and human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) had a similar specificity for translesion synthesis past Pt-DNA adducts (dien >> oxaliplatin >/= cisplatin > JM216). Primer extension assays performed in the presence of high mobility group protein 1 (HMG1), which is known to recognize cisplatin-damaged DNA, revealed that inhibition of translesion synthesis by HMG1 also depended on the carrier ligand of the Pt-DNA adduct (cisplatin > oxaliplatin = JM216 >> dien). These data were consistent with the results of gel-shift experiments showing similar differences in the affinity of HMG1 for DNA modified with the different platinum adducts. Our studies show that both DNA polymerases and damage-recognition proteins can impart specificity to replicative bypass of Pt-DNA adducts. This information may serve as a model for further studies of translesion synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brautigam, C. A., & Steitz, T. A. (1998) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(98)80010-9 · Cited by 377
Cited by
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
“The bulky diaminocyclohexane (DACH) carrier ligand of oxaliplatin is thought to contribute to the differential replicative bypass and binding of damage-recognition proteins on the platinated DNA, thereby conferring less cross-resistance and enhanced activit”
BackgroundJohnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 396
Self-citationModifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Ta, L. E., Espeset, L., Podratz, J., & Windebank, A. J. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.04.010 · Cited by 325
DNA Polymerase γ in Mitochondrial DNA Replication and Repair
Graziewicz, M. A., Longley, M. J., & Copeland, W. C. (2006) · Chemical Reviews · doi:10.1021/cr040463d · Cited by 301
Self-citationLongley, M. J., Nguyen, D., Kunkel, T. A., & Copeland, W. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105230200 · Cited by 270
Self-citationMitochondrial DNA damage and its consequences for mitochondrial gene expression
Cline, S. D. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.06.002 · Cited by 203
RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult
Bosco, E. E. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkg919 · Cited by 97
Differential activation of DNA-PK based on DNA strand orientation and sequence bias
Pawelczak, K. S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki157 · Cited by 42
Metadata
- Authors
- Vaisman, A., Lim, S. E., Patrick, S. M., Copeland, W. C., Hinkle, D. C., Turchi, J. J., & Chaney, S. G.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-08-01
- Volume
- 38
- Issue
- 34
- Pages
- 11026-11039
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2010001472
- Cited by
- 137
- References
- 1
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.